“Global Small Animal Imaging (In-Vivo) Market is anticipated to grow on account of technological advancements, increasing use of pre-clinical imaging and growing number of research and pharmaceutical companies”, says Visiongain report

05 September 2019
Pharma

Visiongain has launched a new pharma report Small Animal Imaging (In-Vivo) Market Report 2019-2029: By Modality (Optical Imaging, PET, SPECT, CT, MRI, Ultrasound, Photoacoustic Imaging, Magnetic Particle Imaging), Reagent (Optical Imaging Reagents, Contrast Agents, PET Tracers, SPECT Probes) and Region.

Global Small Animal Imaging (In-Vivo) Market is anticipated to grow on account of technological advancements, increasing use of pre-clinical imaging and growing number of research and pharmaceutical companies. The global Small Animal Imaging (In-Vivo) market is anticipated to grow at a lucrative CAGR of 11.3% and anticipated to reach USD 3.32 Billion by 2029.

Small animal imaging (In vitro) is a method used in the imaging of biological procedures in living animals that demonstrates changes in cell activity to study drug effects and progression of disease. Small animal imaging is used for drug development and different disease drug evaluation during clinical studies. Small animal imaging includes digital angiography, micro MRI, micro CT, micro SPECT, X-ray imaging and magnetic particle imaging. Small animal (primarily mice) in vivo imaging is increasingly implemented throughout the drug development phase, especially in the therapeutic area of oncology / cancer.

Currently the most widely used imaging modalities are PET, optical (bioluminescence and fluorescence), and MRI. Single modality imaging prevails, with multi-modality presently being accessed primarily through co-registration with other imaging methods for instance PET+CT. In vivo imaging in research studies is anticipated to have the biggest effect on drug development by tracking the progression of disease and therapeutic reaction. The most commonly used reagents in imaging studies are PET tracers (e.g. Fluorine-18 based) and bioluminescent markers / reporters (e.g. luciferins, proluciferins).  

North America holds majority of market share followed by Europe. Growth is attributed to rising  pre-clinical research, increased public-private investment to promote the manufacturing of radioisotopes, government support for pharmaceutical and biotechnology R&D, and increasing demand for rapid and advanced methods among others. On the other hand, favorable R&D platform and supportive regulatory scenario across Asian economies are stimulating the growth of the small animal imaging market in the region.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as Agilent Technologies, Inc., Aspect Imaging, Berthold Technologies, Bioscan, Inc., Bruker Corporation, FUJIFILM Holdings Corporation, Gamma Medica-Ideas, Inc., Genovis Ab, LI-COR Biosciences, Life Technologies Corporation, Mediso Ltd., MILabs B.V., Miltenyi Biotec GmbH, MR Solutions Ltd., PerkinElmer, Inc, Promega Corporation, Inc., Siemens AG, Spectral Instruments Imaging, Thermo Fisher Scientific and Trifoil Imaging among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Diagnostic Imaging market set to grow to $32bn by 2024” says Visiongain report

Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.

20 September 2019

Read

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
Do NOT follow this link or you will be banned from the site!